[Immune response to the vaccine (Hepavax B) against the B virus].
40 volunteers were vaccinated with a vaccine against hepatitis B (Hepavex B). All vaccines were at high risk to develop hepatitis B. After the third dose 37 (92.5%) of the vaccines, developed antibodies (HBsAb). The group more exposed to the virus B developed antibodies earlier, after the first dose. It is especulated that the earlier response could be anamnestic, due to previous inaparent contact with B virus. There were not serius side effects due to the vaccination.